Alkermes (ALKS) Gets Tentative Scheduling for VIVITROL NDA Review from U.S. FDA

Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company’s supplemental New Drug Application (sNDA) for VIVITROL (naltrexone for extended-release...

Read More